Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)(Regulatory Post Marketing Commitment Plan).

Trial Profile

Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)(Regulatory Post Marketing Commitment Plan).

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2012

At a glance

  • Drugs Linezolid (Primary)
  • Indications Vancomycin-resistant enterococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 29 Jun 2012 Actual patient number changed from 15 to 41as reported by ClinicalTrials.gov.
    • 06 Jun 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
    • 06 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top